Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04833101
Other study ID # JSVCT115
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 7, 2021
Est. completion date March 4, 2022

Study information

Verified date March 2022
Source Jiangsu Province Centers for Disease Control and Prevention
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, observer-blind, placebo-controlled study, for evaluation of safety and immunogenicity of heterologous prime-boost immunization of recombinant COVID-19 vaccine (adenovirus type-5 vector) and RBD-based protein subunit vaccine (ZF2001) against COVID-19 in Chinese healthy population. 120 healthy subjects aged over 18 years of age who have been vaccinated with recombinant adenovirus type-5 vectored vaccine will be recruited in this study. Of them, 60 subjects will be enrolled in the "0-28 days" regimen and other 60 will be enrolled in "0-56 days" regimen. Subjects, 30 of them are 18-59 years old and 30 are 60 years old and above in each regimen will be randomly vaccinated with the second dose of subunit vaccine(ZF2001) against COVID-19 or a commercial influenza vaccine in a ratio of 2:1. They will then be vaccinated with the third dose of ZF2001 on month 4 after the second dose. The occurrence of adverse events within 28 days and serious adverse events within 6 months after the last vaccination will be observed. In addition, blood samples will be collected on day 0 before the second vaccination, day 14, 28 after the second vaccination and day 14, month 6 after third vaccination to test serum antibody levels and to profile the immune cells' subgroups and germlines. Each subject will remain in this study for approximately 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date March 4, 2022
Est. primary completion date September 18, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The subjects = 18 years old who has completed one dose of recombinant Ad5 vectored COVID-19 vaccine. - The subjects can provide with informed consent and sign informed consent form (ICF). - The subjects are able to and willing to comply with the requirements of the clinical trial program and can complete the 6-month follow-up of the study. - Axillary temperature = 37.0 ? - Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination and clinical judgment of the investigator and meet the requirements of these products immunization. Exclusion Criteria: - have a medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. - be allergic to any component of the research vaccines, or used to have a history of hypersensitivity or serious reactions to vaccination. - Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan within six months. - have acute febrile diseases and infectious diseases. - have severe chronic diseases or condition in progress cannot be smoothly controlled, such as asthma, diabetes, thyroid disease - Congenital or acquired angioedema / neuroedema. - have the history of urticaria 1 year before receiving the trial vaccine. - have asplenia or functional asplenia. - have thrombocytopenia or other coagulation disorders (which may cause contraindications for intramuscular injection). - have the history of immunosuppressive therapy, anti allergy therapy, cytotoxic therapy or inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, and acute corticosteroid therapy without dermatitis) over the past 6 months. - have received blood products within 4 months before injection of trial vaccines. - have received another investigational product within one month before injection of trial vaccine. - have received attenuated vaccine within 1 month before injection of trial vaccine except the recombinant Ad5 vectored COVID-19 vaccine. - have received subunit or inactivated vaccine within 14 days before the vaccination with trial vaccine. - under anti tuberculosis treatment. - not be able to follow the protocol, or not be able to understand the informed consent according to the researcher's judgment, due to various medical, psychological, social or other conditions.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
recombinant Ad5 vectored COVID-19 vaccine
This vaccine contains 5×10^10 virus particles of recombinant replication defective human type-5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.
RBD-based protein subunit vaccine (ZF2001) against COVID-19
This is a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19, made by using CHO cell, 25µg/dose, produced by Anhui Zhifei Longcom Biopharmaceutical Co.,Ltd.
trivalent split influenza vaccine
This vaccine contains 15 µ g H1NI, 15 µ g H3N2 and 15 µ g B-series hemagglutinin, produced by Dalian Aleph Biomedical Co., Ltd.It is a liquid dosage form, 0.5 ml / bottle.

Locations

Country Name City State
China Jiangsu Provincial Center for Diseases Control and Prevention Nanjing Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Jiangsu Province Centers for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Types of binding antibodies IgG against SARS-CoV-2 S protein at day 14, day 28 after the second vaccination and day 14, month 6 after the third vaccination. Types of binding antibodies IgG against SARS-CoV-2 S protein at day 14, day 28 after the second vaccination and day 14, month 6 after the third vaccination. at day 14, day 28 after the second vaccination and day 14, month 6 after the third vaccination.
Other Cross neutralizing of the antibodies to variants of SARS-CoV-2 measured by pseudovirus neutralization test at Day 28 after the booster vaccination. Cross neutralizing of the antibodies to variants of SARS-CoV-2 measured by pseudovirus neutralization test at Day 28 after the booster vaccination. At Day 28 after the booster vaccination.
Other The immune cells' subgroups and germlines at Day 28 after vaccination. The immune cells', such as B cells and T cells, subgroups and germlines at Day 28 after vaccination. At Day 28 after vaccination.
Primary Incidence of solicited adverse events within 7 days after vaccination. Incidence of solicited adverse events within 7 days after vaccination. Within 7 days after vaccination
Primary GMT of neutralizing antibodies against live SARS-CoV-2 virus at Day 14 after the booster vaccination. GMT of neutralizing antibodies against live SARS-CoV-2 virus at Day 14 after the booster vaccination. At Day 14 after the booster vaccination
Secondary Incidence of adverse reactions within 28 days after vaccination. Incidence of adverse reactions within 28 days after vaccination. Within 28 days after vaccination
Secondary Incidence of adverse events within 28 days after vaccination. Incidence of adverse events within 28 days after vaccination. Within 28 days after vaccination.
Secondary Incidence of unsolicited AE within 28 days after vaccination. Incidence of unsolicited adverse events within 28 days after vaccination. Within 28 days after vaccination.
Secondary Incidence of serious adverse events(SAE) from the first dose to the 6 months after completing the last dose of vaccination. Incidence of serious adverse events(SAE) from the first dose to the 6 months after completing the last dose of vaccination. From the first dose to the 6 months after completing the last dose of vaccination.
Secondary GMT of binding antibodies against SARS-CoV-2 S and RBD protein measured by ELISA at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination. GMT of binding antibodies against SARS-CoV-2 S and RBD protein measured by ELISA at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination. at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination.
Secondary Proportion of the participants with at least a four-fold increase of the binding antibodies against SARS-CoV-2 S and RBD protein at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination. Proportion of the participants with at least a four-fold increase of the binding antibodies against SARS-CoV-2 S and RBD protein at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination. at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination.
Secondary Fold increase of binding antibodies against SARS-CoV-2 S and RBD protein at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination. Fold increase of binding antibodies against SARS-CoV-2 S and RBD protein measured by ELISA, as compared to baseline, at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination. at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination.
Secondary GMT of neutralizing antibodies against live SARS-CoV-2 virus at day 28 after the second vaccination, and day 14, month 6 after the third vaccination GMT of neutralizing antibodies against live SARS-CoV-2 virus at day 28 after the second vaccination, and day 14, month 6 after the third vaccination at day 28 after the second vaccination, and day 14, month 6 after the third vaccination
Secondary Proportion of the participants with at least a four-fold increase of neutralizing antibodies against live SARS-CoV-2 virus at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination. Proportion of the participants with at least a four-fold increase of neutralizing antibodies against live SARS-CoV-2 virus, as compared to baseline, at day 28 after the second vaccination, and day 14, month 6 after the third vaccination. at day 14, day 28 after the second vaccination, and day 14, month 6 after the third vaccination.
Secondary Fold increase of neutralizing antibodies against live SARS-CoV-2 virus at day 14, day 28 after the second vaccination and day 14, month 6 after the third vaccination. Fold increase of neutralizing antibodies against live SARS-CoV-2 virus, as compared to baseline, at day 14, day 28 after the second vaccination and day 14, month 6 after the third vaccination. at day 14, day 28 after the second vaccination and day 14, month 6 after the third vaccination.
See also
  Status Clinical Trial Phase
Recruiting NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Active, not recruiting NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Spikogen Booster Study Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure